Agios Pharmaceuticals (AGIO) Total Liabilities (2012 - 2026)

Agios Pharmaceuticals' Total Liabilities history runs 15 years deep, the most recent figure standing at $75.9 million for Q1 2026.

• Quarterly Total Liabilities fell 14.74% year-over-year to $75.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.9 million (down 14.74% YoY) and the FY2025 annual result came in at $104.1 million, down 14.83% from the prior year.
• Total Liabilities was $75.9 million for Q1 2026 at Agios Pharmaceuticals, down from $104.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $165.1 million in Q3 2024 and bottomed at $75.9 million in Q1 2026.
• A 5-year average of $116.8 million and a median of $120.4 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 37.13% — and 2025, when it tumbled 38.61%.
• Agios Pharmaceuticals' Total Liabilities stood at $137.9 million in 2022, then dropped by 8.56% to $126.1 million in 2023, then dropped by 3.06% to $122.2 million in 2024, then fell by 14.83% to $104.1 million in 2025, then dropped by 27.12% to $75.9 million in 2026.
• Business Quant data shows AGIO's Total Liabilities at $75.9 million in Q1 2026, $104.1 million in Q4 2025, and $101.4 million in Q3 2025.